Please assess the completion status of the following clinical trial:

Trial Title: IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
PAPP-A2 deficient~Inclusion Criteria:~* Defect in PAPP-A2 (heterozygous or homozygous mutation)~Exclusion Criteria:~* None~Healthy Volunteers~Inclusion Criteria:~* Between the ages of 18 and 30~* In general good health~Exclusion Criteria:~* Any medications (with the exception of contraceptives)~* Pregnancy

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PAPP-A2 deficient patients (Type: EXPERIMENTAL): Patients deficient in PAPP-A2 with short stature will be treated with Increlex (rhIGF-1)

Based on this trial design, predict the completion outcome and termination type (if applicable).